Filtered By:
Cancer: Lung Cancer
Therapy: Gene Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer
ConclusionThe results showed that the PDL1-targeted albumin liposome could be used as a high efficient delivery vector of siRNA, and was a high efficient and safe nano vector for tumor targeted gene therapy.
Source: Journal of Cancer Research and Clinical Oncology - July 1, 2023 Category: Cancer & Oncology Source Type: research

Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery
J Control Release. 2022 Nov 10:S0168-3659(22)00739-8. doi: 10.1016/j.jconrel.2022.10.061. Online ahead of print.ABSTRACTWith the rapid development of biopharmaceuticals and the outbreak of COVID-19, the world has ushered in a frenzy to develop gene therapy. Therefore, therapeutic genes have received enormous attention. However, due to the extreme instability and low intracellular gene expression of naked genes, specific vectors are required. Viral vectors are widely used attributed to their high transfection efficiency. However, due to the safety concerns of viral vectors, nanotechnology-based non-viral vectors have attrac...
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Hezhi Wang Lu Qin Xin Zhang Jian Guan Shirui Mao Source Type: research

Long non-coding RNA LUCAT1 regulates the RAS pathway to promote the proliferation and invasion of malignant glioma cells through ABCB1
In this study, the role of lung cancer associated transcript 1 (lncRNA LUCAT 1) in glioma occurrence and development, as well as its possible regulatory mechanism, was explored. We utilized the gene chip technology in the preliminary experiment, and based on the experiment results, selected LUCAT1（NONHSAT102745）, which was significantly upregulated in glioma, and ATP-binding cassette Subfamily B member l (ABCB1), which was significantly down-regulated in co-expression analysis, for study. Next, the expression of LUCAT1 and ABCB1 in cells and tissues was immediately evaluated. Subsequently, the cells were transfected wi...
Source: Cell Research - October 21, 2022 Category: Cytology Authors: Xia Wu Lvmeng Song Xiangrong Chen Yalan Zhang Shun Li Xiaoping Tang Source Type: research

Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer
CONCLUSION: The results showed that the PDL1-targeted albumin liposome could be used as a high efficient delivery vector of siRNA, and was a high efficient and safe nano vector for tumor targeted gene therapy.PMID:35997823 | DOI:10.1007/s00432-022-04298-2
Source: Cell Research - August 23, 2022 Category: Cytology Authors: Liming Zhang Guangke Xie Xin Xiao Chao Cheng Source Type: research

Current Drug Targeting using siRNAbased Nano Therapeutics for Pulmonary Diseases
Curr Pharm Des. 2022 Jul 27. doi: 10.2174/1381612828666220727144223. Online ahead of print.ABSTRACTThe importance of siRNA in nano drug delivery systems to target important pulmonary disorders such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and others is reviewed in this perspective. The great majority of lung illnesses are caused by protein misfolding. As a result, siRNA-based therapies are increasingly being used to target the gene. Given the difficulties of delivering bare siRNA, siRNA protection may ensure its efficacy in gene therapy. These issues could be solved with a nano-based siRNA deli...
Source: Current Pharmaceutical Design - July 27, 2022 Category: Drugs & Pharmacology Authors: Venkateshwaran Krishnaswami Ruckmani Kandasamy Source Type: research

A targeted siRNA ‐loaded PDL1‐exosome and functional evaluation against lung cancer
ConclusionThe PD-L1 targeting exosome can be used as an efficient siRNA delivery carrier, which is an efficient and safe nanocarrier for tumor targeted gene therapy.
Source: Thoracic Cancer - May 12, 2022 Category: Cancer & Oncology Authors: Xianbin Lin, Liangan Lin, Jingyang Wu, Wentan Jiang, Jiayun Wu, Jianshen Yang, Chun Chen Tags: ORIGINAL ARTICLE Source Type: research

Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells.
Authors: Cao Z, Wu W, Wei H, Zhang W, Huang Y, Dong Z Abstract Histone-lysine N-methyltransferase EZH2 (EZH2) is the principle component of the polycomb repressive complex 2 (PRC2)/embryonic ectoderm development protein-EZH2 complex, which promotes tumorigenesis by repressing transcription of tumor suppressor genes. EZH2 is considered a key marker in several types of cancer, such as colorectal and prostate cancer. However, the molecular mechanisms and clinical value of EZH2 in lung cancer have not yet been fully investigated. The aim of the present study was to investigate the functions of EZH2 in lung cancer progr...
Source: Oncology Letters - November 27, 2020 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

A novel tumour suppressor lncRNA F630028O10Rik inhibits lung cancer angiogenesis by regulating miR-223-3p.
In this study, we carried out RNA sequencing (RNA-Seq) of tumour tissues isolated from LLC tumour-bearing mice treated with either Plasmodium yoelli (Py)-infected red blood cells or uninfected red blood cells. We found that F630028O10Rik (abbreviated as F63) is a novel lncRNA that was significantly up-regulated in tumours isolated from mice treated with Py-infected red blood cells compared to the control. By using gene silencing technique, F63 was found to inhibit both tumour Vascular Endothelial Growth Factor A (VEGFA) secretion and endothelial cells clone formation, migration, invasion and tube formation. Injection of ch...
Source: J Cell Mol Med - February 12, 2020 Category: Molecular Biology Authors: Qin L, Zhong M, Adah D, Qin L, Chen X, Ma C, Fu Q, Zhu X, Li Z, Wang N, Chen Y Tags: J Cell Mol Med Source Type: research